Pfizer pares back Haleon stake in £2.5bn sale.


Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares in a £2.5bn sale.

  • Haleon
  • 15 January 2025 08:49:11
Haleon

Source: Sharecast

The Wall Street firm sold the stock at 357p per ordinary share, raising around £2.5bn and reducing its 15% stake to 7.3%.

The British consumer healthcare firm - which owns Sensodyne toothpaste, Centrum vitamins and Tums, among others - was originally part of pharmaceuticals firm GSK.

It was formed through the integration of Novartis’ consumer healthcare portfolio in 2015 and Pfizer’s in 2019.

It was spun out of GSK, then called GlaxoSmithKline, in a blockbuster 2022 listing. GSK took a 13.5% stake in the blue chip, while Pfizer retained its 32% holding in the business.

However, the firm behind the Comirnaty Covid-19 vaccine has since started reducing its position, including a £2.4bn sale last autumn.

GSK has also been selling down its holding, and offloaded its remaining 4.2% stake in May last year

Shares in Haleon ticked up 1% as trading got underway on Wednesday, to 370.2p.


ISIN: GB00BN7SWP63
Exchange: London Stock Exchange
Sell:
1,430.50 p
Buy:
1,431.00 p
Change: 23.00 ( 1.63 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.